Novel 1α-hydroxy Vitamin D4 and novel analogues, 1,25 dihydroxy Vitamin D4 and 1,24 dihydroxy Vitamin D4 which are useful for the treatment of disorders of calcium metabolism. Preparation of the novel 1α-hydroxy Vitamin D4 starts from ergosterol which is converted in six steps to 22,23-dihydroergosterol. 22,23-dihydroergosterol was irradiated to yield Vitamin D4 which was converted in four steps to 1α-hydroxy Vitamin D4 using a cyclovitamin procedure which produced the novel intermediates, Vitamin D4 tosylate, 3,5 cyclovitamin D4 and 1α-hydroxy cyclovitamin D4. 1,25 dihydroxy Vitamin D4 and 1,24 dihydroxy Vitamin D4 are isolated as biological products of the metabolism of novel 1α-hydroxy Vitamin D4 using cultured human liver cells.
|
1. 1α-hydroxy Vitamin D4.
|
|||||||||||||||||||||||||||||||||||
This is a continuation of application Ser. No. 07/991,493 filed Dec. 17, 1992, now abandoned, which is a continuation of application Ser. No. 07/800,045, filed Nov. 29, 1991, now abandoned, which is a continuation of application Ser. No. 07/586,854, filed Sep. 21, 1990, now abandoned.
This invention relates to biologically active Vitamin D4 compounds. More specifically, this invention relates to novel 1α-hydroxy Vitamin D4 and novel intermediates used in its synthesis, novel 1,25 dihydroxy Vitamin D4 and novel 1,24 dihydroxy Vitamin D4.
Vitamin D is known to be important in the regulation of calcium metabolism in animals and man. See, Harrison's Principals of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism, Chapter 335," in E. Braunwald, K. J. Isselbacher, R. G. Petersdorf, J. D. Wilson, J. B. Martin and A. S. Fauci (eds.), Calcium, Phosphorous, and Bone Metabolism: Calcium Regulating Hormones, McGraw-Hill, New York, 1987, pp. 1860-1865. The two most commonly known, useful forms of Vitamin D are Vitamin D3 and Vitamin D2. Vitamin D3 is synthesized endogenously in the skin of animals and man, whereas Vitamin D2 is the form of Vitamin D supplied by plants. Vitamin D2 differs from Vitamin D3 in that it contains a double bond between C22 and C23 and further contains a C24-methyl group. In man and rats, Vitamin D3 and Vitamin D2 have equivalent biopotency.
Vitamin D4, also known as irradiated 22-dihydroergosterol or 22,23-dihydro Vitamin D2 or 22,23-dihydroergocalciferol, differs from Vitamin D3 in that it contains a C24 methyl group. Vitamin D4 was first described in 1936. Grab, W., Z. Physiol. Chem., 243:63 (1936); McDonald, F. G., J. Biol. Chem., 114:IVX (1936). See also Windhaus, A. and Trautmann, G., Z. Physiol. Chem., 247:185-188 (1937). These references report some disagreement as to the level of biological activity of the Vitamin suggesting that in the rat, Vitamin D4 is one-third or three-fourths as active as Vitamin D3 and in the chick, either one-tenth or one-fifth as active as Vitamin D3.
A more definitive study of the biological activity of Vitamin D4 was made by DeLuca, et. al., in 1968. DeLuca, H. F., Weller, M., Blunt, J. W. and Neville, P. F., Arch. Biochem. Biophys., 124:122-128 (1968). There, the authors confirmed that Vitamin D4 was less active than Vitamin D3. DeLuca, et. al., reports that in their hands Vitamin D4 is two-thirds as active as Vitamin D3 or Vitamin D2 in the rat, and one-fifth as active as Vitamin D3 in the chick.
DeLuca, et. al., make reference to the fact that "[t] the synthesis of Vitamin D4 has apparently been little used since it was first described by Windhaus and Trautmann," and comment, "this is perhaps due to the fact that Vitamin D4 is only of academic interest."
To applicants' knowledge, Vitamin D4 has remained "only of academic interest" as applicants are unaware of any further study of Vitamin D4 since that reported by DeLuca, et. al. In fact, The Merck Index states with respect to Vitamin D4, "Its biological activity seems doubtful." "Merck Index," S. Budavari (ed.), 11th ed., Merck & Co., Rathway, N.J., 1989, pp. 1579, #9930.
Since DeLuca, et. al., discovered the active form of Vitamin D3, 1,25-dihydroxy Vitamin D3, (U.S. Pat. No. 3,697,559) and its synthetic precursor, 1α-hydroxy Vitamin D3, (U.S. Pat. No. 3,741,996) most interest has centered on developing therapeutic uses of these active Vitamin D3 metabolites. Unfortunately, while the Vitamin D3 metabolites held great promise as therapeutic agents, this promise has never been fully realized because of the extreme toxicity of these agents. What is needed is a biopotent Vitamin D metabolite of low toxicity such that the drug is practical as a therapeutic agent.
The novel compounds of the invention 1α-hydroxy Vitamin D4, 1,25-dihydroxy Vitamin D4 and 1,24-dihydroxy Vitamin D4, are bioactive forms of Vitamin D4. The present inventors have discovered that these active forms of Vitamin D4 display much greater biopotency than would be predicted on the basis of the previously reported bioassays of Vitamin D4. The present inventors have also discovered, that the bioactive novel compounds are less toxic than would be predicted on the basis of their biopotency. This combination of high activity with low toxicity makes the compounds of the invention useful as therapeutic agents in the treatment of disorders of calcium metabolism.
In order to study the novel compounds of the invention, it was necessary to develop processes for their production. One alpha-hydroxy vitamin D4 was made synthetically and in the course of that synthesis novel intermediates were also produced. 1,25-dihydroxy Vitamin D4 and 1,24-dihydroxy Vitamin D4 are isolated as biological products of the metabolism of 1α-hydroxy Vitamin D4. The following disclosure describes the novel compounds and the processes for their production.
The biologically active compounds of the present invention have the following general formula (I): ##STR1## wherein: R1 is either H or OH, and
R2 is either H or OH but R1 and R2 cannot both has OH.
FIG. 1 depicts the synthesis of vitamin D4 from ergosterol. FIG. 2 depicts the synthesis of 1α-hydroxy vitamin D4 from vitamin D4.
Synthesis of 1α-hydroxy Vitamin D4 was accomplished according to the plan presented in the schema of FIGS. 1 and 2. The synthesis began with ergosterol as the starting material which was converted in six steps to 22,23-dihydroergosterol (VIII) according to the procedure of Barton, et. al., JCS Perkin I, 1976, 821-826. 22,23-dihydroergosterol was then irradiated as described in Windhaus, et. al., Z. Physiol. Chem., 1937, 147:185, to yield Vitamin D4 [22,23-dihydroergocalciferol] (IX). See, FIG. 1. Vitamin D4 was then converted in four steps to 1α-hydroxy Vitamin D4 using a procedure analogous to that described by Paaren, et. al., J. Org. Chem., 1980, 45:3253.
Ergosterol (II) was converted to ergosterol acetate (III) by dissolving 100 g. (0.25 mol.) ergosterol in 600 ml. of anhydrous pyridine and 68 ml. (0.7 mol.) acetic anhydride. The solution was stirred overnight at room temperature after which time the solution was cooled by adding 1.2L. ice, causing a precipitate to form. The precipitate was washed five times with 400 ml. portions of water, then once with 400 ml. of CH3 CN. The resulting product was air dried to yield 79 g. (71%) of ergosterol acetate as a white crystalline solid. m.p.: 169°-171°C; 1 H NMR: (400 MHz, CDCl3), δppm 2.05 (3H, s, 3β-CH3 CO), 4.65.about. 4.75 (1H, m, 3α-H) 5.15.about. 5.25 (2H, m, 22-H and 23-H), 5.4 (1H, d, 6-H), 5.6 (1H, d, 7-H) FTIR [KBr] 1734 cm-1 (C=O stretching) 968 cm-1 (C-H bending).
Ergosterol acetate (III) was dissolved in 2.5L. freshly distilled deoxygenated toluene. To this solution 9 ml. (0.111 mol.) chromyl chloride dissolved in 240 ml. dry CH2 CL2 was added under nitrogen at -78°C over a thirty minute period. The reaction system was stirred at -78°C for an additional fifteen minutes and then 62 ml. of a saturated solution of sodium borohydride in ethanol was added in one portion. After stirring at -78°C for an additional fifteen minutes, the reaction solution was poured into a two phase system of 3N hydrochloric acid (3L.) and benzene (3L.). The organic layer was separated, then washed with water (2L.), twice with a brine solution (2×1L.) and then dried with anhydrous MgSO4. The dried solution was filtered and concentrated in vacuo. The crude crystalline product was then treated with CH3 CN (280ml.) and filtration of the thus formed slurry yielded 12.5g. (41%) of white crystalline 3β-Acetoxy-6α-chloroergosta-7,22-dien-5α-ol (IV). m.p.: 190°-192°C; 1 H NMR: (400 MHz, CDCl3), βppm 2.05 (3H, s, 3β-OAc), 4.65 (1H, d, 6β-H), 5.1 (1H, s, 7-H), 5.1.about.5.3 (2H, m, 22-H and 23-H), FTIR [KBr] 1732 cm-1 (C=O stretching), 968 cm-1 (C-H bending), 3437 cm-1 (O-H stretching).
The 3β-Acetoxy 6α-chloroergosta-7,22-dien-5α-ol (IV) (21.4 g., 0.044 mol.) in dry THF (900 ml.) was added slowly to a stirred suspension of lithium aluminium hydride (2.66 g., 0.07 mol.) in dry THF (750 ml.) at room temperature under nitrogen. The mixture was refluxed for three hours and cooled to 0°C Excess hydride was decomposed with saturated Na2 SO4 solution. Filtration through anhydrous Na2 SO4 and evaporation of the filtrate gave a solid, which was treated directly with acetic anhydride (110 ml.) and dry pyridine (220 ml.) at 0°C Removal of solvent under reduced pressure yielded the acetate (12.75 g., 61%), 3β-Acetoxyergosta-7,22-dien-5α-ol (V). m.p.: 229°-232°C; FTIR [KBr] 1736 cm-1 (C=O stretching), 3460 cm-1 (O-H stretching), 972 cm-1 (C-H bending).
3β-Acetoxyergosta-7,22-dien-5α-ol (V) (2.5 g., 0.0055 mol.) was shaken for sixteen hours with freshly prepared PtO2 (0.5 g.) in ethyl acetate (820 ml.) under H2 gas (15 lbs/sq. in.). The catalyst was removed by filtration and evaporation of the filtrate gave the crude acetate which was dissolved in CH2 CL2 and chromatographed on silica gel. Elution with CH2 Cl2 gave substantially pure 3β-Acetoxyergost-7-en-5α-ol (VI) (2.15 g., 85%) as a white crystalline material. m.p.: 228°-232°C; 1 H NMR: (400 MHz, CDCl3), δppm 2.05 (3H, s, 3β-OAc), 5.05.about. 5.20 (2H, m, 3α-H and 7-H) FTIR [KBr] 1736 cm-1 (C=O stretching), 3462 cm-1 (O-H stretching).
Redistilled thionyl chloride (9.7 ml.) in dry pyridine (170 ml.) was added to compound 3β-Acetoxyergost-7-en-5α-ol (VI) (12.0 g., 0.0262 mol.) in dry pyridine (800 ml.) at 0°C under nitrogen. After 2.5 hours, the solution was diluted with ice cold H2 O (1.5 L.) and extracted with two portions of ether (2.5 L.+1.5 L.). The combined ether extracts were washed with a NaHCO3 solution (1.0 L×2), then 1N HCl (1.5 L.×2) and then water (1 L.). The ether solution was dried with MgSO4, and after filtration, evaporated under reduced pressure to yield a crude product which was converted to a slurry with CH3 CN (100 ml.). The product was collected by filtration and recrystallized from CH3 CN to yield 4.5 g. (39%) of a white crystalline 22,23-dihydroergosteryl acetate (VII). m.p.: 144°-147°C; 1 H NMR: (400 MHz, CDCl3), δppm 2.05 (3H, s, 3β-OAc), 4.65.about. 4.75 (1H, m, 3α-H), 5.4 (1H, d, 6-H), 5.6 (1H, d, 7-H) FTIR [KBr] 1734 cm-1 (C=O stretching).
Compound 22,23-dihydroergosteryl acetate (VII) (4.8 g., 0.011 mol.) was added at once to a stirred suspension of lithium aluminium hydride (2.5 g., 0.066 mol.) in dry ether (1.1 L.) at room temperature. The mixture was stirred for two hours at room temperature. 5N NaOH was added to destroy excess lithium aluminium hydride and H2 O (500 ml.) was then added. The aqueous solution was then extracted with four 250 ml. portions of ether. The combined ether extracts and combined organic layer were washed with brine solution (1 L.), then dried with Na2 SO4. Evaporation of ether under reduced pressure gave the compound, 22,23-dihydroergosterol, (VIII) (4.1 g., 94%) as a white crystalline material. m.p.: 147°-150°C; 1 H NMR: (400 MHz, CDCl3), δppm 3.6.about. 3.7 (1H, m, 3α-H), 5.4 (1H, d, 6H), 5.6 (1H, d, 7-H) FTIR [KBr] 3400 cm-1 (O-H stretching).
22,23-dihydroergosterol (VIII) (2.0 g., 5.0 mmol.) was dissolved in a solution of diethyl ether and benzene (4:1, 600 ml.) and irradiated (Hannovia immersion lamp 450 watts) with stirring under argon in a water cooled quartz vessel for three hours. The solution was concentrated in vacuo to yield a gummy liquid, redissolved in 100 ml. of ethanol and heated at reflux under argon for eight hours. Then, the solution was concentrated in vacuo and the residue was adsorbed on a silica gel column and eluted with 30% ethyl acetate in hexane to afford Vitamin D4 (22,23-dihydroergocalciferol) (IX). 1.2 g. (60%). 1 H NMR: (400 MHz, CDCl3), δppm 0.55 (3H, s, 18-H3) 0.78 (6H, dd, 26-H3 and 27-H3) 0.87 (3H, d, 21-H3) 0.93 (3H, d, 28-H3) 3.94 (1H, m, 3-H) 4.82 (1H, m (sharp), 19-H), 5.04 (1H, m (sharp), 19-H), 6.04 (1H, d, 7-H) 6.24 (1H, d, 6-H).
To a stirred solution of Vitamin D4 (IX) (3.0 g., 7.5 mmol.) in 10 ml. of dry pyridine was added freshly recrystallized p-toluenesulfonyl chloride (3.6 g., 19 mmol.) at 0°C The reaction mixture was stirred at 5°C or 24 hours and was then quenched by pouring the mixture over ice and saturated NaHCO3 (100 ml.) with stirring. The aqueous suspension was extracted with CH2 Cl2 (3×300 ml.). The combined organic extracts were washed with 10% HCl (3×200 ml.), saturated NaHCO3 (3×200 ml.) and saturated NaCl (2×200 ml.) , dried over MgSO4 and concentrated in vacuo to yield 3.5 g. (84%) of the novel intermediate compound Vitamin D4 tosylate (X) . 1 H NMR (400 MHz, CDCl3), δppm 0.54 (3H, s, 18-H3) 0.78 (6H, dd, 26-H 3 and 27-H3) 0.87 (3H, d, 21-H3), 0.96 (3H, d, 28-H3) 2.45 (3H, s, CH3 (tosylate) 4.68 (3H, m, 3-H) 4.82 (1H, m (sharp), 19-H) 5.04 (1H, m (sharp), 19-H), 5.95 (1H, d 7-H), 6.09 (1H, d, 6-H) 7.34 and 7.79 (4H, d, aromatic).
To a stirred suspension of NaHCO3 (17.0 g., 202 mmol.) in methanol (200 ml.) was added dropwise to a solution of Vitamin D4 tosylate (X) (3.5. g., 6.3 mmol.) in dry CH2 Cl2 (10 ml.). The reaction mixture was refluxed overnight under argon. Cooled to room temperature and concentrated in vacuo to about 50 ml. The reaction concentrate was diluted with ether (600 ml.), washed with water (3×300 ml.), dried over MgSO4 and concentrated in vacuo and the residue was passed through a silica gel column and eluted with 10% ethyl acetate in hexane to afford the novel intermediate compound 3,5 cyclovitamin D4 (XI) (heavy oil) 1.5 g. (58%). 1 H NMR (400 MHz, CDCl3), δppm 0.56 (3H, s, 18-H3) 0.78 (6H, dd, 26-H3 and 27-H3), 0.87 (3H, d, 21-H3), 0.94 (3H, d, 28-H3), 3.28 (3H, s, OCH3) 4.2 (1H, d, 6-H), 4.91 (1H, m (sharp), 19-H), 4.98 (1H, d 7-H), 5.08 (1H, m (sharp), 19-H).
Anhydrous tert-butyl hydroperoxide in toluene (3M) (2.6 ml., 7.8 mmol.) was added to a stirred suspension of selenium dioxide (0.22 g., 2 mmol.) in dry CH2 Cl2 (150 ml.) in a three necked flask. The mixture was stirred for three hours under argon. Pyridine (0.3 ml., 3.7 mmol.) was then added and then cyclovitamin D4 (XI) (1.5 g., 3.6 mmol.) was introduced as a solution in CH2 Cl2 (50 ml.). After stirring for thirty minutes, 10% aqueous NaOH solution (200 ml.) was added and then the reaction mixture was diluted with ether (500 ml) and the phases were separated. The organic phase was washed with 10% NaOH (3×200 ml.), water (2×200 ml.) and saturated NaCl solution (2×200 ml.), dried over MgSO4 and concentrated in vacuo. The residue was absorbed on a silica gel column and eluted with 30% ethyl acetate in hexane to afford 0.45 g. (29%) of the novel intermediate compound 1α-hydroxy 3,5-cyclovitamin D4 (XII) (oil). 1 H NMR (400 MHz, CDCl3), δppm 0.54 (3H, s, 18-H3) 0.78 (6H, dd, 26-H3 and 27-H3) 0.86 (3H, d, 21-H3) 0.95 (3H, d, 28-H3) 3.26 (3H, s, OCH3) 4.2 (1H, d, 6-H), 4.22 (1H, m, 1-H), 4.95 (1H, d 7-H), 5.18 (1H, d, 19-H) 5.25 (1H, d, 19-H).
A solution of 1α-hydroxy 3,5-cyclovitamin D4 (XII) (0.45 g., 1.05 mmol.) in a solution of dimethyl sulfoxide (4.5 ml.) and glacial acetic acid (3.6 ml.) was heated to 50°C under argon for one hour. The reaction mixture was then poured over ice and saturated NaHCO3 solution (100 ml.) and extracted with ether (3×200 ml.). The combined ether extracts were washed with saturated NaHCO3 solution (3×200ml.), water (3×200 ml.) and saturated NaCl solution (3×200 ml.), dried over MgSO4, concentrated in vacuo to give a mixture containing 5,6-cis and 5,6-trans 1α-hydroxy Vitamin D4 (about 4:1 by 1 H NMR), 0.4g, (92%). The mixture of 5,6-cis and 5,6-trans 1α-hydroxy Vitamin D4 (0.4 g., 0.97 mmol.) was dissolved in ethyl acetate (25 ml.) and treated with freshly recrystallized maleic anhydride (0.08 g., 0.8 mmol.). This reaction mixture was heated to 35°C under argon for 24 hours. After evaporation of the solvent in vacuo, the crude mixture was chromatographed over a silica gel column using ethyl acetate and hexane (1:1) as eluent, to afford the novel active form of Vitamin D4, 5,6-cis 1α-hydroxy Vitamin D4 (XIII) 90 mg. (23%). m.p.: 128°-130°C IR νmax (Neat) 3400 cm-1 (OH stretching). 1 H NMR (400 MHz, CDCl3), δppm 0.55 (3H, s, 18-H) 0.79 (6H, dd, 26-H3 and 27-H3) 0.87 (3H, d, 21-H3) 0.94 (3H, d, 28-H3), 4.24 (1H, m, 3-H), 4.44 (1H, m, 1-H), 5.02 (1H, m (sharp), 19-H), 5.34 (1H, m (sharp), 19-H), 6.02 (1H, d 7-H), 6.4 (1H, d, 6-H). Mass spectrum [CI] m/e (relative intensity) 415 (M+1, 41%) 397, (M+1-OH 100%), 379 (27%), 135 (22%).
Male weaning rats were fed a Vitamin D deficient diet containing normal Ca (0.47%) and P (0.3%). After four weeks on this diet the rats had serum calcium values less than 7 mg/dl. The rats were then separated into four groups and orally administered either 1α-hydroxy Vitamin D4 or the vehicle for each of 14 days. Twenty-four hours after the last dose, the rats were killed and the blood calcium measured by a standard laboratory technique.
The results of these determinations are shown in Table 1.
| TABLE 1 |
| ______________________________________ |
| Increase in serum calcium concentration |
| Serum calcium |
| Number concentration |
| Dose of (mg/100 ml) |
| Compound (mcg/kg/day) |
| rats ± Standard Deviation |
| ______________________________________ |
| Vehicle - 10 6.1 ± 0.48 |
| 1α-OH-D4 |
| 0.042 8 7.1 ± 0.80 |
| 1α-OH-D4 |
| 0.250 7 11.6 ± 0.45 |
| 1α-OH-D4 |
| 1.500 9 12.7 ± 0.37 |
| ______________________________________ |
The data of table 1 indicate that 1α-hydroxy Vitamin D4 is effective at increasing serum calcium in the Vitamin D deficient rat and that the response appears to be dose dependent. Surprisingly, the level of the response appears to compare favorably to that reported by Wientroub, et. al., for 1,25 dihydroxy Vitamin D3 administered to Vitamin D deficient rats under experimental conditions similar to those described above. See, Wientroub, S., Price, P. A., Reddi, A. H., "The Dichotomy in the Effects of 1,25 dihydroxy Vitamin D3 and 24,25 dihydroxy Vitamin D3 on Bone GammaCarboxyglutamic Acid-Containing Protein in Serum and Bone in Vitamin D-Deficient Rats," Calcif. Tissue Int. (1987) 40:166-172.
The acute oral toxicity of 1α-OH-D4 in rats was assessed by determining the mean lethal dose (LD50). Rats were fed a standard laboratory diet for 8-10 weeks. Five animals of each sex were administered one oral dose of 1α-OH-D4. The animals were observed for 14 days, and the number of deaths noted. The LD50 value was determined to be about 1.0 mg/kg in males and 3.0 mg/kg in females.
For comparison, the LD50 value for 1α-hydroxy Vitamin D2 under the same conditions was found by applicant's to be 1.7 and 1.8 mg./kg. in male and female rats, respectively. The toxicity of 1α-hydroxy Vitamin D2 has previously been reported as less than 1α-hydroxy Vitamin D3. Sjoden, G., Smith, C., Lindgren, U., and DeLuca, H. F., Proc. Soc. Experimental Biol. Med., 178:432-436 (1985).
The experimental drug 1α-hydroxy Vitamin D4 is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,25 dihydroxy Vitamin D4. The 1,25 metabolite is isolated and purified by high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies demonstrate that the 1,25 dihydroxy Vitamin D4 has good binding affinity for the mammalian Vitamin D receptor protein indicating it is biologically active. The procedures used are similar to that described by Strugnell, et. al., Biochem. Pharm. Vol. 40:333-341 (1990).
Generation and isolation of 1,24 dihydroxy Vitamin D4 is accomplished as described in Example 2, above. The experimental drug 1α-hydroxy Vitamin D4 is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,24 dihydroxy Vitamin D4. The 1,24 metabolite is isolated and purified using high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies with the new metabolite demonstrate that the metabolite has good binding affinity for the mammalian Vitamin D receptor protein which indicates the drug is biologically active.
Bishop, Charles W., Knutson, Joyce C., Moriarty, Robert M.
| Patent | Priority | Assignee | Title |
| 6376479, | Apr 03 1995 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| 6503893, | Dec 30 1996 | Bone Care International, Inc | Method of treating hyperproliferative diseases using active vitamin D analogues |
| 6538037, | Jan 08 1991 | Bone Care International, Inc | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| 6566353, | Dec 30 1996 | Bone Care International, Inc | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| 6573256, | Dec 30 1996 | Bone Care International, Inc | Method of inhibiting angiogenesis using active vitamin D analogues |
| 6680309, | Dec 30 1996 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| 6900191, | Feb 25 1997 | ONCQUEST, INC | 1α-Hydroxyvitamin D5, its synthesis and use in cancer prevention |
| 6903083, | Jul 18 2000 | Genzyme Corporation | Stabilized hydroxyvitamin D |
| 6929797, | Feb 13 1997 | Bone Care International, Inc | Targeted therapeutic delivery of vitamin D compounds |
| 7094775, | Jun 30 2004 | Bone Care International, Inc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| 7122530, | May 29 1998 | Genzyme Corporation | 24-hydroxyvitamin D, analogs and uses thereof |
| 7148211, | Sep 18 2002 | Genzyme Corporation | Formulation for lipophilic agents |
| Patent | Priority | Assignee | Title |
| 2383446, | |||
| 4195027, | Jan 16 1978 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| 4202829, | Jan 05 1978 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| 4260549, | May 21 1979 | WISCONSIN ALUMNI RESEARCH FOUNDATION, A CORP OF WIS | Process for preparing 1α-hydroxylated compounds |
| 4362710, | Jul 04 1980 | Nissan Gosei Kogyo Co., Ltd. | Feeds for baby pigs, process for preparing the same and method of breeding baby pigs |
| 4661294, | Mar 18 1985 | General Hospital Corporation | Biologically active 1-thio derivatives of vitamin D |
| 4866048, | Aug 02 1985 | LEO PHARMACEUTICAL PRODUCTS LTD A S LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESEISKAB | Novel vitamin D analogues |
| 5157135, | Mar 31 1989 | Nisshin Seifun Group Inc | 1α,25-dihydroxyvitamin D4 compounds, ergosta-5,7-diene compounds and processes for the preparation thereof |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Aug 24 1994 | Lunar Corporation | (assignment on the face of the patent) | / | |||
| Dec 12 1996 | Lunar Corporation | Bone Care International, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 008296 | /0676 | |
| Mar 24 1998 | Lunar Corporation | BONE CARE INTENATIONAL, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009328 | /0485 |
| Date | Maintenance Fee Events |
| Jul 20 1999 | M283: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Jan 27 2000 | ASPN: Payor Number Assigned. |
| Jul 30 2003 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
| Dec 10 2003 | ASPN: Payor Number Assigned. |
| Dec 10 2003 | RMPN: Payer Number De-assigned. |
| Feb 27 2006 | STOL: Pat Hldr no Longer Claims Small Ent Stat |
| Jul 30 2007 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Date | Maintenance Schedule |
| Jan 30 1999 | 4 years fee payment window open |
| Jul 30 1999 | 6 months grace period start (w surcharge) |
| Jan 30 2000 | patent expiry (for year 4) |
| Jan 30 2002 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jan 30 2003 | 8 years fee payment window open |
| Jul 30 2003 | 6 months grace period start (w surcharge) |
| Jan 30 2004 | patent expiry (for year 8) |
| Jan 30 2006 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jan 30 2007 | 12 years fee payment window open |
| Jul 30 2007 | 6 months grace period start (w surcharge) |
| Jan 30 2008 | patent expiry (for year 12) |
| Jan 30 2010 | 2 years to revive unintentionally abandoned end. (for year 12) |